asthma
ASTHMA
Asthma is a chronic inflammatory disease of the airways in the lungs of children and adults.
The patient usually complains of shortness of breath, chest tightness and coughing with wheezing.
Goals of treatment are effective symptom control with minimal or no exacerbations, minimal or no nocturnal and daytime symptoms, no limitations on activities, minimal or no need for reliever treatment, and minimal adverse effects of medication.

Asthma Drug Information

Drug Information

Indication: Bronchial asthma. Respules: Acute laryngotracheobronchitis (croup) in infants & childn.

Indication: Regular treatment of COPD including chronic bronchitis & emphysema. Accuhaler: Regular treatment of asthma...

Spiolto Respimat
olodaterol + tiotropium bromide

Indication: Maintenance bronchodilator treatment for symptomatic relief in adult patients w/ COPD.

Indication: Maintenance bronchodilator treatment for symptomatic relief of COPD. Add-on maintenance bronchodilator treatme...

Indication: Regular treatment of asthma where use of combination (inhaled corticosteroid & long-acting β2

Indication: Bronchodilator for maintenance treatment of bronchospasm associated w/ COPD including chronic bronchitis &...

Indication: Bronchodilator for maintenance treatment of bronchospasm, associated w/ COPD, including chronic bronchitis, em...

Indication: Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ rever...

Indication: Bronchodilator for the prevention & treatment of symptoms in chronic obstructive airway disorders w/ rever...

Indication: Symptomatic treatment of acute asthma attacks; bronchial asthma & other conditions w/ reversible airway na...

1  /  16
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Pearl Toh, 5 days ago
Gefapixant, a first-in-class non-narcotic, oral P2X3 receptor antagonist, significantly reduces cough frequency in patients with refractory or unexplained chronic cough, according to two COUGH* studies presented at ERS 2020.
Roshini Claire Anthony, Yesterday

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.